New study tracks safety of eplontersen in patients with liver transplants
NCT ID NCT07654855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study monitors the long-term safety of eplontersen, a treatment for transthyretin amyloidosis, in patients who have had a liver transplant or have severe liver impairment. Researchers will track side effects, lab changes, and serious health events in about 320 participants. The goal is to fill gaps in knowledge about how eplontersen affects these specific groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide crucial safety data on eplontersen for patients with liver issues, potentially expanding treatment options for transthyretin amyloidosis.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by small sample sizes or incomplete data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis
- Carpal tunnel surgery could spot hidden heart disease risk
- AI spots heart clues in bone scans: a new way to catch a silent killer?
- Can MRI and nerve tests catch a rare disease before symptoms start?
- New italian registry aims to unlock secrets of rare heart disease
- Protein clues could spot rare disease years early